FDA announces end to Wegovy and Ozempic drug shortages

Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
FDA declares end to Wegovy and Ozempic shortage
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock.
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
End of Ozempic, Wegovy shortage means copycats must stop production
The FDA says the nationwide shortage for Ozempic and Wegovy is over, but as CBS News New York's Ali Bauman explains, that supply change could lead to consumers paying more.
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
Semaglutide shortage ends as FDA sets deadline for compounders
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.